Solid Biosciences Inc. Restructuring Charges
Solid Biosciences Inc. (SLDB) reported Restructuring Charges of -$63.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2025-03-06
- Solid Biosciences Inc. restructuring charges for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Solid Biosciences Inc. restructuring charges for the quarter ending 2023-09-30 was $0.00.
- Solid Biosciences Inc. restructuring charges for the quarter ending 2023-06-30 was -$63.00K, a 104.14% decline year-over-year.
- Solid Biosciences Inc. restructuring charges for the quarter ending 2022-12-31 was $5.66M.
- Solid Biosciences Inc. restructuring charges for fiscal 2023 was -$63.00K, a 100.88% decline from fiscal 2022.
- Solid Biosciences Inc. restructuring charges for fiscal 2022 was $7.18M.
- Solid Biosciences Inc. restructuring charges for fiscal 2020 was $1.94M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | -$63.00K derived: sum of 3 quarters · filed 2025-03-06 | -$63.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$63.00K derived: sum of 2 quarters · filed 2024-11-06 | -$63.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$63.00K 10-Q · filed 2024-08-13 | -$63.00K 10-Q · filed 2024-08-13 | ||
| 2022-12-31 | $5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $5.66M derived: sum of 2 quarters · filed 2024-03-13 | $7.18M derived: sum of 3 quarters · filed 2024-03-13 | $7.18M 10-K · filed 2024-03-13 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | $1.52M derived: sum of 2 quarters · filed 2023-08-14 | $1.52M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $1.52M 10-Q · filed 2023-08-14 | $1.52M 10-Q · filed 2023-08-14 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $1.94M 10-K · filed 2023-03-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $1.94M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $1.94M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $1.94M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |